Clozapine toxicity after abrupt smoking cessation
A 34-year-old Omani man with schizophrenia, ill for nine years, has been stable on clozapine 400 mg at night for three years. He has smoked 25 cigarettes daily since his teens. Twenty days ago he stopped smoking abruptly after his father's death. Over the last five days his sister reports increasing sleepiness, drooling at night, unsteady gait and "talking to himself" again; today he is confused and has had two brief jerks of the arms. Vital signs: pulse 118/min, BP 132/80 mmHg, temperature 37.8 °C, oxygen saturation 97%. He is drowsy, disoriented to place, has a coarse tremor and brisk reflexes, and myoclonic jerks are observed. Bloods: white cell count 3.8 × 10⁹/L, absolute neutrophil count 1.35 × 10⁹/L, CRP 14 mg/L, creatine kinase 320 U/L. Four months earlier the ANC was 4.1 × 10⁹/L. He takes no other medication and has no infective focus.
1. Explain the likely cause of this presentation with the pharmacokinetic reasoning, and state what else must be excluded.
Read the worked answer
This is clozapine toxicity precipitated by smoking cessation. Tobacco smoke contains polycyclic aromatic hydrocarbons that induce CYP1A2, the main enzyme metabolising clozapine. While he smoked, clearance was high and 400 mg gave a therapeutic level. On stopping, induction resolves over one to three weeks, clearance falls, and the same dose produces levels roughly 1.5–2 times higher - matching the timing and the classic syndrome of sedation, drooling, ataxia, confusion, myoclonus and tachycardia. The CRP of 14 mg/L suggests intercurrent inflammation, which independently suppresses CYP1A2 and compounds the rise.
Exclude: neuroleptic malignant syndrome (rigidity is not lead-pipe and CK is only 320, which argues against it, but serial CK is needed); serotonin syndrome (no serotonergic drug, although myoclonus is shared); sepsis or aspiration pneumonia, which can themselves raise clozapine levels and cause delirium; anticholinergic toxicity; alcohol or benzodiazepine withdrawal; post-ictal state; and metabolic causes such as hyponatraemia, hypercalcaemia and hypoglycaemia. Check a clozapine level, repeat CK and CRP, take blood cultures and chest radiograph, and obtain an ECG looking at QT and for myocarditis features.
2. Give your immediate management, including whether clozapine should be stopped and how you would manage the neutrophil count.
Read the worked answer
Stop clozapine temporarily. There is no antidote, so management is supportive: protect the airway given drooling and drowsiness, nurse in a monitored environment, maintain hydration, treat any infection identified, and avoid other sedating or QT-prolonging drugs. Monitor vital signs, CK, renal function and CRP at least daily, and obtain troponin and an echocardiogram if fever, tachycardia or chest symptoms raise the possibility of myocarditis.
Regarding the neutrophil count: an ANC of 1.35 × 10⁹/L is mild neutropenia, not agranulocytosis, and is not by itself a reason for permanent discontinuation. Repeat the full blood count to exclude a laboratory artefact and check the previous trend. Continue twice-weekly full blood counts and stop clozapine permanently only if the ANC falls below 1.0 × 10⁹/L, with urgent haematology input; below 0.5 × 10⁹/L he needs protective isolation and filgrastim. Benign ethnic neutropenia is common in Arab and African populations, but his documented baseline of 4.1 × 10⁹/L makes a genuine decline more likely, so do not dismiss it.
Rechallenge only after the level has fallen and the confusion and myoclonus have resolved, and inform the family of the reason for the dose change.
3. Plan his longer-term treatment, including restarting or adjusting clozapine and the counselling he and his family need.
Read the worked answer
Restart clozapine at a substantially lower dose, approximately 200–250 mg at night, because he is no longer smoking; a reasonable rule is a 30–50% reduction, then titrate against a trough level taken 12 hours after the dose, targeting 350–600 ng/mL. Reassess after five days at steady state and adjust in steps of 50–100 mg rather than by large jumps. Continue full blood count monitoring according to the clozapine protocol and repeat levels after any change in smoking, inflammation or interacting drugs.
Counselling points for him and his family: never stop or restart smoking abruptly, and tell the team if his smoking changes, because the same dose will no longer be right; avoid caffeine loading and interacting drugs such as fluvoxamine and ciprofloxacin; report fever, sore throat, drowsiness, drooling, muscle jerks or palpitations immediately; continue treatment for constipation, which is a significant cause of morbidity on clozapine.
Address the grief over his father, which is likely to affect adherence and smoking behaviour, and arrange psychosocial support. Document the plan explicitly in his record and give him written information, since this is a predictable and preventable recurrence.